CTMX Fundamental Analysis - CYTOMX THERAPEUTICS INC

Fundamental Rating

CTMX gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 555 industry peers in the Biotechnology industry. Both the profitability and the financial health of CTMX get a neutral evaluation. Nothing too spectacular is happening here. While showing a medium growth rate, CTMX is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

CTMX had positive earnings in the past year.

In the past year CTMX has reported a negative cash flow from operations.

In the past 5 years CTMX reported 4 times negative net income.

In the past 5 years CTMX reported 4 times negative operating cash flow.

1.2 Ratios

With an excellent Return On Assets value of 42.24%, CTMX belongs to the best of the industry, outperforming 99.28% of the companies in the same industry.

The Return On Equity of CTMX (166.09%) is better than 99.46% of its industry peers.

With an excellent Return On Invested Capital value of 58.82%, CTMX belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	42.24%
ROE	166.09%
ROIC	58.82%

ROA(3y)-3.97%

ROA(5y)-11.04%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

CTMX's Profit Margin of 28.19% is amongst the best of the industry. CTMX outperforms 96.76% of its industry peers.

Looking at the Operating Margin, with a value of 24.37%, CTMX belongs to the top of the industry, outperforming 96.58% of the companies in the same industry.

		Industry Rank	Sector Rank
OM	24.37%
PM (TTM)	28.19%
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

CTMX has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.

The number of shares outstanding for CTMX has been increased compared to 1 year ago.

Compared to 5 years ago, CTMX has more shares outstanding

There is no outstanding debt for CTMX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

CTMX has an Altman-Z score of -3.13. This is a bad value and indicates that CTMX is not financially healthy and even has some risk of bankruptcy.

CTMX has a Altman-Z score of -3.13. This is comparable to the rest of the industry: CTMX outperforms 47.03% of its industry peers.

CTMX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-3.13

ROIC/WACC6.54

WACC8.99%

2.3 Liquidity

CTMX has a Current Ratio of 1.73. This is a normal value and indicates that CTMX is financially healthy and should not expect problems in meeting its short term obligations.

CTMX's Current ratio of 1.73 is on the low side compared to the rest of the industry. CTMX is outperformed by 79.64% of its industry peers.

CTMX has a Quick Ratio of 1.73. This is a normal value and indicates that CTMX is financially healthy and should not expect problems in meeting its short term obligations.

Looking at the Quick ratio, with a value of 1.73, CTMX is doing worse than 78.56% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	1.73
Quick Ratio	1.73

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 145.00% over the past year.

CTMX shows a strong growth in Revenue. In the last year, the Revenue has grown by 23.82%.

Measured over the past years, CTMX shows a quite strong growth in Revenue. The Revenue has been growing by 19.15% on average per year.

EPS 1Y (TTM)145%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%58.82%

Revenue 1Y (TTM)23.82%

Revenue growth 3Y54.7%

Revenue growth 5Y19.15%

Sales Q2Q%22.8%

3.2 Future

Based on estimates for the next years, CTMX will show a very negative growth in Earnings Per Share. The EPS will decrease by -36.33% on average per year.

CTMX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.77% yearly.

EPS Next Y-155.58%

EPS Next 2Y-78%

EPS Next 3Y-54.3%

EPS Next 5Y-36.33%

Revenue Next Year-35.17%

Revenue Next 2Y-39.19%

Revenue Next 3Y-47.27%

Revenue Next 5Y6.77%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 5.10, which indicates a rather cheap valuation of CTMX.

98.74% of the companies in the same industry are more expensive than CTMX, based on the Price/Earnings ratio.

Compared to an average S&P500 Price/Earnings ratio of 27.45, CTMX is valued rather cheaply.

The Forward Price/Earnings Ratio is negative for CTMX. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	5.1
Fwd PE	N/A

4.2 Price Multiples

CTMX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. CTMX is cheaper than 98.20% of the companies in the same industry.

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	7.48

4.3 Compensation for Growth

A cheap valuation may be justified as CTMX's earnings are expected to decrease with -54.30% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-78%

EPS Next 3Y-54.3%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

CTMX does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

CYTOMX THERAPEUTICS INC

NASDAQ:CTMX (7/3/2025, 7:14:29 PM)

After market: 2.47 -0.03 (-1.2%)

2.5

+0.02 (+0.81%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)05-12 2025-05-12/bmo

Earnings (Next)08-06 2025-08-06/amc

Inst Owners51.04%

Inst Owner Change-3.11%

Ins Owners0.54%

Ins Owner Change22.99%

Market Cap393.85M

Analysts83.33

Price Target5.61 (124.4%)

Short Float %13.31%

Short Ratio3.46

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)164.34%

Min EPS beat(2)113.47%

Max EPS beat(2)215.22%

EPS beat(4)4

Avg EPS beat(4)128.46%

Min EPS beat(4)45.28%

Max EPS beat(4)215.22%

EPS beat(8)8

Avg EPS beat(8)145.07%

EPS beat(12)9

Avg EPS beat(12)93.52%

EPS beat(16)11

Avg EPS beat(16)67.59%

Revenue beat(2)2

Avg Revenue beat(2)77.11%

Min Revenue beat(2)61.87%

Max Revenue beat(2)92.34%

Revenue beat(4)4

Avg Revenue beat(4)66.12%

Min Revenue beat(4)23.14%

Max Revenue beat(4)92.34%

Revenue beat(8)8

Avg Revenue beat(8)66.95%

Revenue beat(12)9

Avg Revenue beat(12)32.42%

Revenue beat(16)9

Avg Revenue beat(16)10.74%

PT rev (1m)46.67%

PT rev (3m)17.37%

EPS NQ rev (1m)10%

EPS NQ rev (3m)-340%

EPS NY rev (1m)-1449.21%

EPS NY rev (3m)53.76%

Revenue NQ rev (1m)-38%

Revenue NQ rev (3m)-55.73%

Revenue NY rev (1m)-26.26%

Revenue NY rev (3m)3.36%

Valuation

		Industry Rank	Sector Rank
PE	5.1
Fwd PE	N/A
P/S	2.67
P/FCF	N/A
P/OCF	N/A
P/B	15.72
P/tB	16.72
EV/EBITDA	7.48

EPS(TTM)0.49

EY19.6%

EPS(NY)-0.46

Fwd EYN/A

FCF(TTM)-0.52

FCFYN/A

OCF(TTM)-0.52

OCFYN/A

SpS0.94

BVpS0.16

TBVpS0.15

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	42.24%
ROE	166.09%
ROCE	74.46%
ROIC	58.82%
ROICexc	N/A
ROICexgc	N/A
OM	24.37%
PM (TTM)	28.19%
GM	N/A
FCFM	N/A

ROA(3y)-3.97%

ROA(5y)-11.04%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score6

Asset Turnover1.5

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	0
Cap/Depr	18.62%
Cap/Sales	0.21%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.73
Quick Ratio	1.73
Altman-Z	-3.13

F-Score6

WACC8.99%

ROIC/WACC6.54

Cap/Depr(3y)42.33%

Cap/Depr(5y)55.65%

Cap/Sales(3y)1.42%

Cap/Sales(5y)2.17%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)145%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%58.82%

EPS Next Y-155.58%

EPS Next 2Y-78%

EPS Next 3Y-54.3%

EPS Next 5Y-36.33%

Revenue 1Y (TTM)23.82%

Revenue growth 3Y54.7%

Revenue growth 5Y19.15%

Sales Q2Q%22.8%

Revenue Next Year-35.17%

Revenue Next 2Y-39.19%

Revenue Next 3Y-47.27%

Revenue Next 5Y6.77%

EBIT growth 1Y232.31%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year281.13%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-33.24%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-34.93%

OCF growth 3YN/A

OCF growth 5YN/A

CYTOMX THERAPEUTICS INC (CTMX) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens